Work Files Saved Searches
   My Account                                                  Search:   Quick/Number   Boolean   Advanced   Derwent    Help   


 The Delphion Integrated View
  Buy Now:   Buy PDF- 7pp  PDF  |   File History  |   Other choices   
  Tools:  Citation Link  |  Add to Work File:    
  View:  Expand Details   |  INPADOC   |  Jump to: 
  Go to:  Derwent  
 Email this to a friend  Email this to a friend 
       
Title: US6011055: Treatment of cystic disease with compounds which stimulate TNF-α production in vivo
[ Derwent Title ]

Country: US United States of America

View Images High
Resolution

 Low
 Resolution

 
7 pages

 
Inventor: Woo, David D.L.; Los Angeles, CA

Assignee: The Regents of the University of California, Oakland, CA
other patents from UNIVERSITY OF CALIFORNIA, THE REGENTS OF (599425) (approx. 4,840)
 News, Profiles, Stocks and More about this company

Published / Filed: 2000-01-04 / 1998-03-13

Application Number: US1998000039309
IPC Code: Advanced: A61K 31/00; A61K 31/19; A61K 31/192; A61K 31/40; A61K 31/403; A61K 31/404; A61K 31/405; A61K 31/4745; A61K 38/00; A61K 38/19; A61K 38/20; A61K 45/00; A61P 13/00; A61P 13/12; A61P 43/00; C07D 209/28; C07D 409/06;
Core: A61K 31/185; A61K 31/4738; C07D 209/00; C07D 409/00; more...
IPC-7: A01N 43/38;

ECLA Code: A61K31/192; A61K31/404; A61K31/405; A61K31/4745; A61K38/19A;

U.S. Class: Current: 514/420; 514/414; 514/569; 514/570;
Original: 514/420; 514/414; 514/569; 514/570;

Field of Search: 514/420,569,570,414

Government Interest:

STATEMENT OF GOVERNMENT SUPPORT
    This invention was made with United States government funding under NIH Grant No. DK 40700. The government may have certain rights in the invention.

Priority Number:
1998-03-13  US1998000039309
1996-03-26  US1996000621629

Abstract: A method for treating polycystic kidney disease in an individual in need thereof. This method includes identifying a mammal having a cystic disease and administering to the mammal a pharmacologically effective anti-cystic amount of TNF-α or an agent which stimulates TNF-α production in vivo. The agent is administered in a pharmacologically acceptable carrier, excipient or diluent.

Attorney, Agent or Firm: Knobbe, Martens, Olson & Bear, LLP ;

Primary / Asst. Examiners: Jones, Dwayne C.;

INPADOC Legal Status: None          Buy Now: Family Legal Status Report

       
Related Applications:
Application Number Filed Patent Pub. Date  Title
US1996000621629 1996-03-26    1998-05-12  Treatment of cystic disease with TNF-α


       
Parent Case:     This application is a continuation of U.S. Application Ser. No. 08/621,629, filed Mar. 26, 1996, now U.S. Pat. No. 5,750,495.

Designated Country: AL AM AP AZ BA BB BG BR BY CU CZ EE GE GH HU IL IS KE KG KP KZ LC  AT BE CH DE DK ES FI FR GB GR IE IT 

Family: Show 12 known family members
First Claim:
Show all 6 claims		 What is claimed is:     1. A method for treating a mammal having a cystic disease, comprising the step of administering to said mammal a pharmacologically effective anti-cystic amount of an agent selected from the group consisting of indomethacin, naproxen, ibuprofen, tenidap and imiquod in a pharmacologically acceptable carrier, excipient or diluent.

Background / Summary: Show background / summary

Drawing Descriptions: Show drawing descriptions

Description: Show description

       
U.S. References: Go to Result Set: No U.S. references   |  No patents reference this one   |   Backward references (0)

       
Foreign References:
Buy
PDF		 Publication Date IPC Code Assignee   Title
Buy PDF- 38pp WO9408041 1994-04  A61K 31/165 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA INHIBITION OF CYST FORMATION BY CYTOSKELETAL SPECIFIC DRUGS 


Other Abstract Info: CHEMABS 127(22)306613V DERABS C1997-489382

Other References:
  • T. Akimoto, et al. (1994) "Antitumor Effect Of DT-5641a, A Synthetic Low-Toxicity Lipid A Analog, Involves Endogenous Tumor Necrosis Factor Induction Subsequent To Macrophage Activation", Int. J. Immunopharmac., 16(11):887-893. (7 pages) Cited by 2 patents [ISI abstract]
  • E.D. Avner, et al. (1992) "Abnormal Sodium Pump Distribution During Renal Tubulogenesis In Congenital Murine Polycystic Kidney Disease", Proc. Natl. Acad. Sci. USA, 89:7447-7451. (5 pages) Cited by 2 patents [ISI abstract]
  • B. Beutler, et al. (1994) "Unraveling Function In The TNF Ligand And Receptor Families", Science 264:667-668. (2 pages) Cited by 17 patents [ISI abstract]
  • A.P. Bollon, et al. (1988) "Human Cytokines, Tumor Necrosis Factor, And Interferons: Gene Cloning, Animal Studies, And Clinical Trials", Journal of Cellular Biochemistry, 36:353-367. (15 pages) Cited by 7 patents
  • E.A. Carswell, et al. (1975) "An Endotoxin-Induced Serum Factor That Causes Necrosis Of Tumors", Proc. Nat. Acad. Sci. USA, 72(9):3666-3670. (5 pages) Cited by 78 patents
  • B.D. Cowley, et al. (1991) "Elevated Proto-Oncogene Expression In Polycystic Kidneys Of The C57BL/6J (CPK) Mouse", J. Am. Soc. Nephrol., 1:1048-1053. (6 pages) Cited by 2 patents [ISI abstract]
  • M.C. Daoust, et al. (1995) "Evidence For A Third Genetic Locus For Autosomal Dominant Polycystic Kidney Disease", Genomics, 25:733-736. (4 pages) Cited by 8 patents [ISI abstract]
  • M.T. Davisson, et al. (1991) "The Mouse Polycystic Kidney Disease Mutation (cpk) Is Located On Proximal Chromosome 12", Genomics, 9:778-781. (4 pages) Cited by 4 patents [ISI abstract]
  • I. Ebihara, et al. (1988) "Altered mRNA Expression Of Basement Membrane Components In A Murine Model Of Polycystic Kidney Disease", Laboratory Investigation, 58(3):262-269. (8 pages) Cited by 4 patents
  • V.H. Gattone II, et al. (1991) "Murine Infantile Polycystic Kidney Disease: A Role For Reduced Renal EpidermalGrowth Factor", American Jour. of Kidney Diseases, XVII(6):606-607. (2 pages) Cited by 2 patents [ISI abstract]
  • S. Golding, et al. (1995) "Tenidap-Modulated Proinflammatory Cytokine Activation Of A Monocyte Cell Line", The Journal of Immunology, 154:5384-5390. (7 pages) Cited by 2 patents [ISI abstract]
  • D.E. Griswold, et al. (1993) "Differentiation In Vivo Of Classical Non-Steroidal Antiinflammatory Drugs From Cytokine Suppressive Antiinflammatory Drugs And Other Pharmacological Classes Using Mouse Tumour Necrosis Factor Alpha Production", Drugs Exptl. Clin. Res., XIX(6):243-248. (6 pages) Cited by 17 patents [ISI abstract]
  • M.A. Harding, et al. (1991) "The SGP-2 Gene Is Developmentally Regulated In The Mouse Kidney And Abnormally Expressed In Collecting Duct Cysts In Polycystic Kidney Disease", Devel. Biol. 146:483-490. (8 pages) Cited by 2 patents [ISI abstract]
  • S. Horikoshi, et al. (1991) "Epidermal Growth Factor (EGF) Expression In The Congenital Polycystic Mouse Kidney", Kidney International, 39:57-62. (6 pages) Cited by 3 patents [ISI abstract]
  • W.J. Kimberling, et al. (1993) "Autosomal Dominant Polycystic Kidney Disease: Localization Of The Second Gene To Chromosome 4q13-q23", Genomics, 18:467-472. (6 pages) Cited by 10 patents [ISI abstract]
  • J. Mandell, M.D., et al. (1993) "Animal Model Of Human Disease: Congential Polycystic Kidney Disease", Am. J. Pathol., 113(1):112-114.
  • D.F. Mangan, et al. (1991) "Lipopolysaccharide, Tumor Necrosis Factor-α, And IL-1β Prevent Programmed Cell Death (Apoptosis) In Human Peripheral Blood Monocytes1 ", The Journal of Immunology, 146:1541-1546. (6 pages) Cited by 11 patents [ISI abstract]
  • R.A. McDonald, et al. (1991) "Inherited Polycystic Kidney Disease In Children", Seminars in Nephrology, 11(6):632-642. (11 pages) Cited by 4 patents [ISI abstract]
  • S.A. Orellana, et al. (1995) "Epidermal Growth Factor Receptor Expression Is Abnormal In Murine Polycystic Kidney", Kidney International, 47:490-499. (10 pages) Cited by 2 patents [ISI abstract]
  • G.M. Preminger, M.D., et al. (1982) "Murine Congenital Polycystic Kidney Disease: A Model For Studying Development Of Cystic Disease", The Journal of Urology, 127:556-560. (5 pages) Cited by 3 patents
  • S.T. Reeders, et al. (1985) "A Highly Polymorphic DNA Marker Linked To Adult Polycystic Kidney Disease On Chromosome 16", Nature, 317:542-544. (3 pages) Cited by 10 patents
  • M.J. Reiter, et al. (1994) "Cytokine Induction In Mice By The Immunomodulator Imiquimod", Journal of Leukocyte Biology, 55:234-240. (7 pages) Cited by 3 patents [ISI abstract]
  • M. Taub. et al. (1990) "Altered Basement Membrane Protein Biosynthesis By Primary Cultures Of CPK/CPK Mouse Kidney", Kidney International, 37:1090-1097. (8 pages) Cited by 3 patents
  • M. Tsujimoto, et al. (1985) "Tumor Necrosis Factor: Specific Binding And Internalization In Sensitive And Resistant Cells", Proc. Natl. Acad. Sci. USA, 82:7626-7630. (5 pages) Cited by 3 patents
  • B.B. Warner, et al. (1991) "Tumor Necrosis Factor-α Increases Mn-SOD Expression: Protection Against Oxidant Injury", The American Physiological Society, L296-L301. (6 pages) Cited by 2 patents [ISI abstract]
  • G.H.W. Wong, et al. (1988) "Induction Of Manganous Superoxide Dismutase By Tumor Necrosis Factor: Possible Protective Mechanism", Science, 242:941-944. (4 pages) Cited by 20 patents
  • D.D. L. Woo, et al. (1994) "Taxol Inhibits Progression Of Congenital Polycystic Kidney Disease", Nature, 368:750-573. (4 pages) Cited by 4 patents [ISI abstract]
  • D. Woo, Ph.D. (1995) "Apoptosis And Loss Of Renal Tissue In Polycystic Kidney Diseases", The New England Journal Of Medicine, 333(1):18-25. (8 pages) Cited by 10 patents [ISI abstract]
  • K. Zerres, et al. (1994) "Mapping Of The Gene For Autosomal Recessive Polycystic Kidney DIsease (ARPKD) To Chromosome 6p21-cen", Nature Genetics, 7:429-432. (4 pages) Cited by 4 patents [ISI abstract]
  • D. Woo, Ph.D. (1994) "Taxol Inhibits Progression Of Progression Of Congenital Polycystic Kidney Disease", Nature 368:750-753. (4 pages) Cited by 4 patents [ISI abstract]


    • Inquire Regarding Licensing

    Powered by Verity
    Plaques from Patent Awards      Gallery of Obscure PatentsNominate this for the Gallery...

    Thomson Reuters Copyright © 1997-2010 Thomson Reuters 
    Subscriptions  |  Web Seminars  |  Privacy  |  Terms & Conditions  |  Site Map  |  Contact Us  |  Help